Understand any stock in simple English
Enter a ticker to learn what the company does and how it makes money.
Diaverum runs kidney dialysis clinics that treat people whose kidneys have failed.
Diaverum is one of the world's largest operators of kidney dialysis clinics. It treats people with chronic kidney disease, whose kidneys can no longer clean their blood on their own. For these patients, dialysis is not optional β it is the difference between life and death, usually several times a week. Diaverum runs the clinics, staffs them, and provides the machines and care that keep those patients going.
The business model is simple to grasp. Diaverum typically gets paid by public health systems or insurers, not by the patients themselves, because dialysis is expensive and almost always covered as essential care. It operates hundreds of clinics across Europe, Latin America, the Middle East, and beyond, often under contracts with governments or through partnerships with local health providers. The company grew out of Gambro Healthcare, a former dialysis arm of the Swedish medical giant Gambro, which was split off and renamed Diaverum in the mid-2000s. Today it is privately owned, backed by investment funds rather than traded on a stock exchange. What makes dialysis a durable business is that demand does not disappear in a recession. Once kidneys fail, patients need treatment for years, often for the rest of their lives. That recurring, non-discretionary need gives clinic operators steady revenue. The flip side is that Diaverum is heavily dependent on government payers, so price pressure and contract renewals matter enormously. It competes with other large dialysis providers and with hospitals that run their own units, and it must keep tight control of staffing and machine costs to stay profitable.
The company's main growth lever is opening or acquiring more clinics, especially in countries where dialysis capacity is thin and populations are aging. Older people and people with diabetes are the fastest-growing group of kidney failure patients worldwide, which is why dialysis demand keeps climbing. Diaverum's bet is that governments will keep outsourcing this care to specialists rather than building it themselves β a bet that has largely paid off as its network has expanded across dozens of countries.
Saved answer Β· last researched 16 Nov 2026